Explore our corporate updates and press releases below. For the latest news, follow us on LinkedIn.
To learn more about our company, visit our Corporate Overview page. To see our progress toward new answers and disease-centric therapies, visit our Pipeline page or review recent articles and studies on our Publications page.
|05/18/2023||May 2023 Update||Corporate Update|
|03/20/2023||Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) Antibody Innate Cell Modulator, ISB 1442||Press Release|
|02/09/2023||February 2023 Update||Corporate Update|
|12/12/2022||Ichnos Sciences Presents Data Supporting Three Oncology Assets at ASH 2022 Annual Meeting||Press Release|
|11/10/2022||November 2022 Update||Corporate Update|
|11/03/2022||Ichnos Sciences Data Selected for Presentation at the 64th ASH Annual Meeting||Press Release|
|09/28/2022||Ichnos Sciences Announces Initiation Of First-In-Human Study For ISB 1442||Press Release|
|08/09/2022||August 2022 Update||Corporate Update|
|06/08/2022||Webcast: Ichnos Sciences Presentation at the 2022 Jefferies Healthcare Conference||Event|
|06/07/2022||Ichnos Sciences To Present At The 2022 Jefferies Healthcare Conference||Press Release|
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.